These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 34507892)

  • 1. The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm.
    Nastasi DR; Norman R; Moxon JV; Quigley F; Velu R; Jenkins J; Golledge J
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):643-650. PubMed ID: 34507892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
    Nastasi DR; Moxon JV; Norman R; Trollope AF; Rowbotham S; Quigley F; Jenkins J; Golledge J
    J Vasc Surg; 2021 Apr; 73(4):1396-1403.e3. PubMed ID: 32891803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.
    Journath G; Hambraeus K; Hagström E; Pettersson B; Löthgren M
    BMC Cardiovasc Disord; 2017 Aug; 17(1):224. PubMed ID: 28814290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
    Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
    Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
    ; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
    Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?
    Vani A; Underberg JA
    Clin Pharmacol Ther; 2018 Aug; 104(2):290-296. PubMed ID: 29882959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL-C Levels Below 55 mg/dl and Risk of Hemorrhagic Stroke: A Meta-Analysis.
    Masson W; Lobo M; Siniawski D; Masson G; Lavalle-Cobo A; Molinero G
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105655. PubMed ID: 33571878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
    ; Baigent C; Blackwell L; Emberson J; Holland LE; Reith C; Bhala N; Peto R; Barnes EH; Keech A; Simes J; Collins R
    Lancet; 2010 Nov; 376(9753):1670-81. PubMed ID: 21067804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
    Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
    Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.